Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr Pharmaceuticals has reported that its subsidiary Barr Laboratories, has received final approval from the FDA for its generic version of Roche Laboratories's Kytril tablets, 1mg.
Subscribe to our email newsletter
The company has received final approval following the expiration of Roche’s patent on December 28, 2007, and plans to launch its product shortly.
Kytril (granisetron hydrochloride) tablets, 1mg (eq to 1mg base) is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, and radiation.